[go: up one dir, main page]

DE602006018057D1 - Substituierte chinolone und verwendungsverfahren - Google Patents

Substituierte chinolone und verwendungsverfahren

Info

Publication number
DE602006018057D1
DE602006018057D1 DE602006018057T DE602006018057T DE602006018057D1 DE 602006018057 D1 DE602006018057 D1 DE 602006018057D1 DE 602006018057 T DE602006018057 T DE 602006018057T DE 602006018057 T DE602006018057 T DE 602006018057T DE 602006018057 D1 DE602006018057 D1 DE 602006018057D1
Authority
DE
Germany
Prior art keywords
substituted
chinolines
use process
compounds
disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602006018057T
Other languages
English (en)
Inventor
Anita Melikian
John Jessen Wright
Antoni Krasinski
Cheng Hu
Aaron Novack
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chemocentryx Inc
Original Assignee
Chemocentryx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemocentryx Inc filed Critical Chemocentryx Inc
Publication of DE602006018057D1 publication Critical patent/DE602006018057D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Catalysts (AREA)
DE602006018057T 2005-11-10 2006-11-13 Substituierte chinolone und verwendungsverfahren Active DE602006018057D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73569205P 2005-11-10 2005-11-10
PCT/US2006/044149 WO2007059108A2 (en) 2005-11-10 2006-11-13 Substituted quinolones and methods of use

Publications (1)

Publication Number Publication Date
DE602006018057D1 true DE602006018057D1 (de) 2010-12-16

Family

ID=38049231

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602006018057T Active DE602006018057D1 (de) 2005-11-10 2006-11-13 Substituierte chinolone und verwendungsverfahren

Country Status (10)

Country Link
US (1) US7557213B2 (de)
EP (2) EP1954274B8 (de)
JP (1) JP5175207B2 (de)
AT (1) ATE486875T1 (de)
AU (1) AU2006315514B2 (de)
CA (1) CA2629461C (de)
DE (1) DE602006018057D1 (de)
DK (1) DK1954274T3 (de)
ES (1) ES2353549T3 (de)
WO (1) WO2007059108A2 (de)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1954274T3 (da) 2005-11-10 2011-01-31 Chemocentryx Inc Substituerede quinoloner og fremgangsmåder til anvendelse
US8216582B2 (en) * 2006-06-23 2012-07-10 Alethia Biotherapeutics Inc. Polynucleotides and polypeptide sequences involved in cancer
US9512236B2 (en) 2006-12-19 2016-12-06 Ablynx N.V. Amino acid sequences directed against GPCRS and polypeptides comprising the same for the treatment of GPCR-related diseases and disorders
WO2009138519A1 (en) 2008-05-16 2009-11-19 Ablynx Nv AMINO ACID SEQUENCES DIRECTED AGAINST CXCR4 AND OTHER GPCRs AND COMPOUNDS COMPRISING THE SAME
GB0716532D0 (en) * 2007-08-24 2007-10-03 Angeletti P Ist Richerche Bio Therapeutic compounds
WO2009036341A2 (en) * 2007-09-14 2009-03-19 The Regents Of The University Of Michigan Compositions and methods relating to hiv protease inhibition
JP2011519856A (ja) 2008-05-01 2011-07-14 メルク・シャープ・エンド・ドーム・コーポレイション ４−オキソ−１，４−ジヒドロキノリンｍ１受容体ポジティブアロステリックモジュレーター
KR20110084280A (ko) 2008-11-03 2011-07-21 알레시아 바이오쎄라퓨틱스 인코포레이티드 종양 항원의 생물 활성을 특이적으로 차단하는 항체
US8853202B2 (en) * 2008-11-04 2014-10-07 Chemocentryx, Inc. Modulators of CXCR7
US20110014121A1 (en) * 2008-11-04 2011-01-20 Chemocentryx, Inc. Modulators of cxcr7
US8288373B2 (en) * 2008-11-04 2012-10-16 Chemocentryx, Inc. Modulators of CXCR7
PL2448938T3 (pl) 2009-06-29 2014-11-28 Incyte Holdings Corp Pirymidynony jako inhibitory PI3K
US8759359B2 (en) * 2009-12-18 2014-06-24 Incyte Corporation Substituted heteroaryl fused derivatives as PI3K inhibitors
TW201130842A (en) * 2009-12-18 2011-09-16 Incyte Corp Substituted fused aryl and heteroaryl derivatives as PI3K inhibitors
WO2011117423A1 (en) 2010-03-26 2011-09-29 Ablynx N.V. Immunoglobulin single variable domains directed against cxcr7
US9193721B2 (en) 2010-04-14 2015-11-24 Incyte Holdings Corporation Fused derivatives as PI3Kδ inhibitors
US9062055B2 (en) 2010-06-21 2015-06-23 Incyte Corporation Fused pyrrole derivatives as PI3K inhibitors
JP6086864B2 (ja) 2010-08-18 2017-03-01 サミュメッド リミテッド ライアビリティ カンパニー カテニンシグナル伝達経路活性化剤としてのジケトンおよびヒドロキシケトン
JP5961187B2 (ja) 2010-12-20 2016-08-02 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Ｐｉ３ｋ阻害剤としてのｎ−（１−（置換フェニル）エチル）−９ｈ−プリン−６−アミン
US8754114B2 (en) 2010-12-22 2014-06-17 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
US10197557B2 (en) 2011-02-24 2019-02-05 The Regents Of The University Of California Small molecules for endothelial cell activation
WO2012125629A1 (en) 2011-03-14 2012-09-20 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as pi3k inhibitors
GB201104600D0 (en) 2011-03-18 2011-05-04 Pronoxis Ab New compounds and medical uses
US9126948B2 (en) 2011-03-25 2015-09-08 Incyte Holdings Corporation Pyrimidine-4,6-diamine derivatives as PI3K inhibitors
JP6181040B2 (ja) 2011-03-28 2017-08-16 アブリンクス エン．ヴェー． 二特異性抗ｃｘｃｒ７免疫グロブリン単一可変ドメイン
CN106146664B (zh) 2011-03-31 2021-09-07 Adc治疗股份有限公司 针对肾相关抗原1的抗体及其抗原结合片段
ES2616477T3 (es) 2011-09-02 2017-06-13 Incyte Holdings Corporation Heterociclaminas como inhibidores de pi3k
RS58918B1 (sr) 2012-01-09 2019-08-30 Adc Therapeutics Sa Agensi za tretman trostruko negativnog raka dojke
JP6211509B2 (ja) 2012-03-02 2017-10-11 武田薬品工業株式会社 複素環化合物およびその用途
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
DK2861595T5 (en) 2012-06-13 2018-01-15 Incyte Holdings Corp Substituted tricyclic compounds as FGFR inhibitors
WO2014026125A1 (en) 2012-08-10 2014-02-13 Incyte Corporation Pyrazine derivatives as fgfr inhibitors
US9777005B2 (en) 2012-11-19 2017-10-03 Takeda Pharmaceutical Company Limited Bicyclic heterocyclic compound containing a substituted pyrrole ring
JP6272897B2 (ja) 2012-11-29 2018-01-31 ケモセントリックス，インコーポレイティド Ｃｘｃｒ７アンタゴニスト
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
HRP20190142T1 (hr) 2013-02-22 2019-03-22 Samumed, Llc Gama-diketoni kao aktivatori signalizacijskog puta wnt/beta-katenina
MY181497A (en) 2013-04-19 2020-12-23 Incyte Holdings Corp Bicyclic heterocycles as fgfr inhibitors
AU2014272718B2 (en) * 2013-05-30 2018-06-28 Idorsia Pharmaceuticals Ltd CXCR7 receptor modulators
GB201409044D0 (en) 2014-05-21 2014-07-02 Ucl Business Plc New compounds
WO2015191677A1 (en) 2014-06-11 2015-12-17 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors
CN105272964B (zh) * 2014-07-08 2017-11-24 河南省医药科学研究院 6‑取代‑1‑((1‑取代苯基‑1,2,3‑三唑‑4‑基)甲基)‑4‑羰基喹啉‑3‑甲酸乙酯类化合物及其制备和应用
BR112017003959B1 (pt) 2014-08-20 2022-08-02 Samumed, Llc Uso de um composto de fórmula i ou um sal dermatologicamente aceitável do mesmo
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
ES2732437T3 (es) 2014-12-01 2019-11-22 Idorsia Pharmaceuticals Ltd Moduladores del receptor de CXCR7
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
AU2016219822B2 (en) 2015-02-20 2020-07-09 Incyte Holdings Corporation Bicyclic heterocycles as FGFR inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
PH12017501538B1 (en) 2015-02-27 2024-02-14 Incyte Holdings Corp Salts of p13k inhibitor and processes for their preparation
WO2016183063A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Crystalline forms of a pi3k inhibitor
WO2016183060A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Process for the synthesis of a phosphoinositide 3-kinase inhibitor
CN108137505B (zh) * 2015-07-17 2021-07-06 富士胶片株式会社 含氮杂环化合物
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
JP2021523121A (ja) 2018-05-04 2021-09-02 インサイト・コーポレイションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ Ｆｇｆｒ阻害剤の固体形態及びその調製プロセス
MA52493A (fr) 2018-05-04 2021-03-10 Incyte Corp Sels d'un inhibiteur de fgfr
CA3101323A1 (en) 2018-06-01 2019-12-05 Incyte Corporation Dosing regimen for the treatment of pi3k related disorders
EP3893882A4 (de) 2018-12-12 2022-08-31 ChemoCentryx, Inc. Cxcr7-hemmer zur behandlung von krebs
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
JP2022539830A (ja) 2019-07-10 2022-09-13 ケモセントリックス，インコーポレイティド Ｐｄ－ｌ１阻害剤としてのインダン
WO2021067374A1 (en) 2019-10-01 2021-04-08 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
AU2020366006A1 (en) 2019-10-14 2022-04-21 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
EP4045037A4 (de) 2019-10-16 2023-11-15 ChemoCentryx, Inc. Heteroaryl-biphenyl-amine zur behandlung von pd-l1-erkrankungen
WO2021076728A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
BR112022006018A2 (pt) 2019-10-16 2022-07-12 Chemocentryx Inc Heteroaril-bifenil amidas para o tratamento de doenças relacionadas à pd-l1
US20230041576A1 (en) * 2019-11-21 2023-02-09 University Of Pittsburgh - Of The Commonwealth System Of Higher Education METHODS AND MATERIALS FOR INHIBITING NF-kB ACTIVITY
EP4069696A1 (de) 2019-12-04 2022-10-12 Incyte Corporation Tricyclische heterocyclen als fgfr-inhibitoren
CN115151539A (zh) 2019-12-04 2022-10-04 因赛特公司 Fgfr抑制剂的衍生物
US12012409B2 (en) 2020-01-15 2024-06-18 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US12065494B2 (en) 2021-04-12 2024-08-20 Incyte Corporation Combination therapy comprising an FGFR inhibitor and a Nectin-4 targeting agent
WO2022261160A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
US4379929A (en) 1981-03-19 1983-04-12 Eli Lilly And Company 4(1H)-Oxocinnoline-3-carboxylic acid derivatives
US5126352A (en) * 1985-06-13 1992-06-30 Schering Corporation Polycyclic quinoline, naphthyridine and pyrazinopyridine derivatives
US5034508A (en) 1988-08-31 1991-07-23 Dai-Ichi Kogyo Seiyaku Co., Ltd. Dispersant for nonaqueous systems
EP0841927B1 (de) * 1995-08-02 2004-01-28 Darwin Discovery Limited Chinolone und deren therapeutische verwendung
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
JP4460221B2 (ja) 2001-05-24 2010-05-12 メルク フロスト カナダ リミテツド １−ビアリール−１，８−ナフチリジン−４−オン系ホスホジエステラーゼ−４阻害薬
US7169750B2 (en) 2001-07-31 2007-01-30 Anormed, Inc. Methods to mobilize progenitor/stem cells
US7253007B2 (en) * 2001-11-30 2007-08-07 Chemocentryx, Inc. Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
US8163769B2 (en) 2002-03-12 2012-04-24 Abbott Laboratories Antibacterial compounds
GB0218630D0 (en) 2002-08-10 2002-09-18 Tanabe Seiyaku Co Novel compounds
US7649011B2 (en) * 2002-12-20 2010-01-19 Chemocentryx, Inc. Inhibitors of human tumor-expressed CCXCKR2
WO2004083207A1 (en) 2003-03-12 2004-09-30 Abbott Laboratories Naphthyridine derivatives as antibacterial agents
DK1954274T3 (da) 2005-11-10 2011-01-31 Chemocentryx Inc Substituerede quinoloner og fremgangsmåder til anvendelse

Also Published As

Publication number Publication date
EP1954274B8 (de) 2011-01-12
EP1954274B1 (de) 2010-11-03
US7557213B2 (en) 2009-07-07
AU2006315514B2 (en) 2012-03-01
DK1954274T3 (da) 2011-01-31
JP5175207B2 (ja) 2013-04-03
CA2629461A1 (en) 2007-05-24
ES2353549T3 (es) 2011-03-03
US20070167443A1 (en) 2007-07-19
CA2629461C (en) 2016-01-12
JP2009515902A (ja) 2009-04-16
WO2007059108A2 (en) 2007-05-24
ATE486875T1 (de) 2010-11-15
EP1954274A2 (de) 2008-08-13
HK1121075A1 (en) 2009-04-17
EP1954274A4 (de) 2009-01-07
WO2007059108A3 (en) 2007-12-13
EP2314590A1 (de) 2011-04-27
AU2006315514A1 (en) 2007-05-24

Similar Documents

Publication Publication Date Title
EP1954274A4 (de) Substituierte chinolone und verwendungsverfahren
CR20130455A (es) Composiciones para el tratamiento de tumores
CR8696A (es) Beta-carbolinas utiles para tratar enfermedades inflamatorias
CY1109985T1 (el) Αναστολεις πρωτεασωματος και μεθοδοι χρησης αυτων
ATE527241T1 (de) Pyridiazinonderivate zur behandlung von tumoren
EP1765391A4 (de) Bakterielle zusammensetzungen zur behandlung von krebs
EA201001143A1 (ru) Активаторы прокаспаз "исполнителей" 3, 6 и 7
PT1881823E (pt) Composições e métodos para o tratamento de transtornos oculares
EP1893216A4 (de) Verfahren und zusammensetzungen zur behandlung von augenerkrankungen
MX2009006704A (es) Derivados de amina triciclicos como inhibidores de proteina de tirosina cinasa.
ATE381558T1 (de) Substituierte pyridinyl und pyrimidinyl derivate als modulatoren eines metabolismus für die behandlung von damit inzusammenhangstehenden krankheiten
NO20082594L (no) Pyrimidinylbenzotiofenforbindelser
IL186217A0 (en) Anti-inflammatory modalities
NO20082425L (no) Formuleringer omfattende jorumycin-, reni-eramycin-, safracin- eller saframycin-relaterte forbindelser for behandling av proliferative sykdommer
WO2006109301A3 (en) Molecules and methods of using same for treating mcp-1/ccr2 associated diseases
CY1111762T1 (el) Διενυδρη παμοϊκη ολανζαπiνη
DE602006013009D1 (de) Pharmazeutische zusammensetzung von mahanin zur behandlung von prostatakrebs
TW200716561A (en) P38 inhibitors and methods of use thereof
EP1904088A4 (de) Zusammensetzungen und verfahren für die krebsbehandlung
ITRM20050179A1 (it) Composizione impiegabile per il trattamento delle patologie paradontali.
IL185653A (en) Antibodies that call for the 1-kim salt region
EP1865952A4 (de) Histaminhaltige zusammensetzung zur behandlung von allergischen erkrankungen
FI20040180L (fi) Koostumus psoriasis-taudin hoitamiseksi
ATE505195T1 (de) Acylglycerophospholipide zur behandlung von krebs-begleiterscheinungen
ATE511394T1 (de) Verwendung von phthalocyanin-derivaten zur nicht- photodynamischen behandlung von erkrankungen